Compare · BDX vs ICUI
BDX vs ICUI
Side-by-side comparison of Becton Dickinson and Company (BDX) and ICU Medical Inc. (ICUI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and ICUI operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $43.58B, about 11.1x ICUI ($3.94B).
- Over the past year, BDX is down 9.8% and ICUI is up 29.8% - ICUI leads by 39.6 points.
- BDX has hit the wire 4 times in the past 4 weeks while ICUI has been quiet.
- BDX has more recent analyst coverage (25 ratings vs 15 for ICUI).
- Company
- Becton Dickinson and Company
- ICU Medical Inc.
- Price
- $158.16-1.07%
- $157.65-2.74%
- Market cap
- $43.58B
- $3.94B
- 1M return
- +8.93%
- +10.79%
- 1Y return
- -9.82%
- +29.79%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1992
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 15
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
ICU Medical Inc.
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree connector products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoLock and ChemoClave closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, including sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation, such as sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. In addition, the company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical Mednet, an enterprise medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. Further, it provides critical care products comprising Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
Latest BDX
- BD to Announce Financial Results for its Third Quarter of Fiscal 2026
- EVP & President Connected Care Muhsin Bilal was granted 14,342 shares and covered exercise/tax liability with 1,935 shares, increasing direct ownership by 43% to 41,359 units (SEC Form 4) (for withholding tax)
- SEC Form 11-K filed by Becton Dickinson and Company
- SEC Form 11-K filed by Becton Dickinson and Company
- EVP, Chief Revenue Officer Feld Michael sold $11,460 worth of shares (75 units at $152.80) as part of a pre-agreed trading plan, decreasing direct ownership by 0.36% to 21,009 units (SEC Form 4)
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $160,226 worth of shares (1,100 units at $145.66) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 13,172 units (SEC Form 4)
- BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System
- New insider Sinha Manish claimed ownership of 8,806 shares (SEC Form 3)
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $166,628 worth of shares (1,100 units at $151.48) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 14,272 units (SEC Form 4)
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
Latest ICUI
- BTIG Research initiated coverage on ICU Medical with a new price target
- SEC Form SD filed by ICU Medical Inc.
- ICU Medical upgraded by Needham with a new price target
- President Woolson Daniel sold $280,685 worth of shares (2,123 units at $132.21), decreasing direct ownership by 9% to 22,479 units (SEC Form 4)
- ICU Medical Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- VP, General Counsel Sanzone Virginia Ruth sold $303,624 worth of shares (2,447 units at $124.08), decreasing direct ownership by 11% to 19,460 units (SEC Form 4)
- Director Kennedy Kolleen T converted options into 1,254 shares, increasing direct ownership by 38% to 4,539 units (SEC Form 4)
- Director Hernandez Laurie converted options into 1,254 shares, increasing direct ownership by 35% to 4,862 units (SEC Form 4)
- Director Finney Elisha W converted options into 1,254 shares, increasing direct ownership by 31% to 5,249 units (SEC Form 4)
- Director Abbey Donald converted options into 1,254 shares, increasing direct ownership by 26% to 6,004 units (SEC Form 4)